Related Experiment Video
Updated: Apr 29, 2026
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
[Biological therapy for osteoporosis]
Shinya Nakamura1, Sakae Tanaka
1Graduate School of Medicine, Surgical Sciences, Orthopaedic Surgery, The University of Tokyo, Japan.
Abstract:
Osteoporosis is a disorder of bone formation and resorption balance. Advances in our knowledge of the molecular mechanisms of bone formation and resorption led to promising therapeutic targets for osteoporosis. In the novel biological drugs, denosumab, a monoclonal antibody against receptor activator of nuclear factor-κB ligand (RANKL) has been clinically applied by positive effect on bone mineral density, negative effect on bone resorption, preventive effect on fragility fractures and safety. Odanacatib, a cathepsin K inhibitor is drawing attention as an antiresorptive drug which has lower bone resorption potency than bisphosphoneate. On the other hand, BHQ-880, an anti-Dickkopf-1 (Dkk-1) antibody and romosozumab (AMG-785) , an anti-sclerostin antibody which activate Wnt/β-catenin signaling pathway are drawing attention as bone formation accelerators with no bone resorption acceleration. Clinical studies of these drugs are now ongoing and their clinical applications are expected.
Insights
Novel osteoporosis drugs target bone formation and resorption. Denosumab, odanacatib, BHQ-880, and romosozumab show promise in clinical trials for treating bone loss and preventing fractures.
Area of Science:
- Endocrinology
- Bone Biology
- Pharmacology
Background:
- Osteoporosis disrupts the balance between bone formation and resorption.
- Understanding molecular mechanisms has revealed new therapeutic targets for osteoporosis treatment.
Purpose of the Study:
- To review novel biological drugs for osteoporosis.
- To highlight emerging therapeutic strategies targeting bone metabolism.
Main Methods:
- Review of current literature on osteoporosis therapeutics.
- Analysis of novel drug classes including monoclonal antibodies and enzyme inhibitors.
Main Results:
- Denosumab, a RANKL inhibitor, improves bone mineral density and reduces resorption and fractures.
- Odanacatib (cathepsin K inhibitor) and BHQ-880 (anti-Dkk-1 antibody) are emerging antiresorptive agents.
- Romosozumab, an anti-sclerostin antibody, promotes bone formation via Wnt signaling.
Conclusions:
- Novel biological drugs offer promising therapeutic avenues for osteoporosis.
- Targeting bone resorption and formation pathways provides new treatment options.
- Ongoing clinical studies are expected to lead to wider clinical applications.
Related Concept Videos
01:40Bone Remodeling
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:31Osteoclasts in Bone Remodeling
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...